Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab

BACKGROUND: Immunotherapy has changed the paradigm of treating non-small cell lung cancer (NSCLC). But, selecting patients who will achieve long-term benefits from treatment remains unsatisfactory. Here, we investigated the possible use of the soluble form of CD8 antigen (sCD8) in predicting durable...

Descripción completa

Detalles Bibliográficos
Autores principales: Siemiątkowska, Anna, Bryl, Maciej, Kosicka-Noworzyń, Katarzyna, Tvrdoň, Jakub, Gołda-Gocka, Iwona, Główka, Franciszek K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870198/
https://www.ncbi.nlm.nih.gov/pubmed/36688998
http://dx.doi.org/10.1007/s00262-023-03377-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870198/
https://www.ncbi.nlm.nih.gov/pubmed/36688998
http://dx.doi.org/10.1007/s00262-023-03377-8

Ejemplares similares